<a id="bm-comp-7ab36ad6-b405-479b-911d-be1807d1709a" name="bm-comp-7ab36ad6-b405-479b-911d-be1807d1709a" class="BMCustomAnchor"></a><table><tr><td bm-component-id="7ab36ad6-b405-479b-911d-be1807d1709a" style="vertical-align: top; width:100.000000%;"><ul><li>Q4 sales -16% vs. ABGSCe, miss in GC&MP and FW</li><li>NW&FT showing positive signs; we see a return to growth in '26e</li><li>We cut '26e-'27e sales by 7% on weaker-than-expected report</li></ul></td></tr></table><a id="bm-comp-50970db6-4803-4a72-861c-c38cc4aeffc2" name="bm-comp-50970db6-4803-4a72-861c-c38cc4aeffc2" class="BMCustomAnchor"></a><table><tr><td bm-component-id="50970db6-4803-4a72-861c-c38cc4aeffc2" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">Q4 results</h3><p>OrganoClick reported Q4 sales of SEK 18m (-16% vs. ABGSCe) and EBIT adj. of SEK -11m (vs. ABGSCe at -5.5m). The sales miss was mostly driven by GC&MP and FW. In GC&MP, sales were particularly weak in December across most segments. Looking ahead, the company’s decision to exit an unprofitable BIOkleen private label agreement implies a ~SEK -4.5m sales headwind for GC&MP (mainly Q1), but with a limited EBIT impact. FW was soft following German distributor inventory replenishment in Q3 and persistent weak demand in Sweden. We expect Sweden to remain sluggish in the near-term but remain positive on the sales development Germany in '26e, which we expect will help FW to reach stabilised levels in FY'26e. The improving NW&FT sales (+17% y-o-y) were a clear positive in Q4, and were partly driven by a volume shift from Q3, but also by slightly improved end-markets.</p><h3 class="bm-h3" style="text-align:left;">Estimate changes and outlook</h3><p>Given the weaker-than-expected Q4 figures, we lower ’26e-’27e sales by 7% and total '26e-'27e EBIT by SEK 9m. We still view the setup into 2026 as improving, supported by NW&FT momentum (we estimate 14% growth in '26e) and the SEK 20m savings programme (almost full effect from Jan-26). Management also expects NW&FT sales from new customers that are planning to launch wipes and food pads.</p><h3 class="bm-h3">Valuation</h3><p>OrganoClick is currently trading at 2.2x-2.1x '26e-'27e EV/Sales vs. peers at 4.6x-1.5x. Although Q4 was weaker than expected, we think the company is set up to reach profitability in '27e with the help of improving end-markets and cost savings in place.</p></td></tr></table>
OrganoClick - Soft end to 2025, better setup into 2026
13 februari 2026